[
    {
        "id": "osp-11598",
        "type": "article-journal",
        "title": "A Case of Amiodarone-Induced Thyrotoxicosis: A diagnostic and therapeutic dilemma",
        "author": [
            {
                "family": "PS",
                "given": "Sudheer Ahamed"
            },
            {
                "family": "Mathew",
                "given": "Abe"
            }
        ],
        "URL": "https://omanscience.com/en/articles/a-case-of-amiodarone-induced-thyrotoxicosis-a-diagnostic-and-therapeutic-dilemma",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Sultan Qaboos University Medical Journal",
        "volume": "9",
        "issue": "3",
        "page": "319-323",
        "DOI": "10.18295/2075-0528.2808",
        "publisher": "Sultan Qaboos University",
        "ISSN": "2075-051X",
        "abstract": "Amiodarone is an iodine rich agent widely used for the treatment of ventricular arrhythmias, paroxysmal supraventricular tachycardia, atrial fibrillation and flutter. However 14-18% of patients treated with amiodarone develop overt thyroid dysfunction in the form of either amiodarone-induced thyrotoxicosis (AIT) or amiodaroneinduced hypothyroidism (AIH). Two different types of AIT have been recognised and designated as Type 1 and Type 2. Distinguishing between the two is often difficult, but necessary for instituting appropriate treatment. We report a case of a 56 year-old male patient who was started on amiodarone for atrial fibrillation and then developed AIT. The challenges in the diagnosis and management of these patients are discussed."
    }
]